Editorial: Model-informed drug development and precision dosing in clinical pharmacology practice
Frontiers in Pharmacology · 30.06.2023 · 14
DOI: 10.3389/fphar.2023.1224980 ↗Kurz gefasst
Editorial in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.06.2023. Verfasst von Ke Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy and School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Editorial on the Research Topic Model-informed drug development and precision dosing in clinical pharmacology practiceModel-informed drug development (MIDD) refers to the integration and quantitative study of physiological, pharmacological, and disease process information using modeling and simulation technology to guide drug development and decision-making, whose aim is to make drug development more efficient and reduce unnecessary patient exposure by integrating data from in vivo/in vitro studies to predict drug effects (Li et al., 2020).Model-informed precision dosing (MIPD) integrates information related to patients, drugs, and diseases through mathematical modeling and simulation technology to provide a basis for precision medicine for patients.Compared with empirical medication, MIPD is a new method to formulate drug administration schedules based on physiological, pathological, genetic, disease, and other characteristics of patients, which can improve the safety, effectiveness, economy, and adherence of pharmacotherapy (Jiao et al., 2021).Common models of MIDD and MIPD include but are not limited to the population pharmacokinetics model, pharmacokinetics/pharmacodynamics model, population pharmacokinetics/pharmacodynamics model, physiologically based pharmacokinetics model, quantitative systems pharmacology, model-based meta-analysis, virtual twin, pharmacoeconomic modeling, artificial intelligence, and machine learning.MIDD and MIPD are essentially the same, given that they solve problems mainly through modeling and simulation.Their differences mainly lie in their different application scenarios, where MIDD mainly refers to modeling and simulation for new drug research and development (Wang et al., 2021;Mitra and
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy and School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Clinical Pharmacology, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
- Department of Pharmacy, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, Jiangsu, China.
- Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zitieren
APA
Hu, K., Fu, M., Huang, X., He, S., Jiao, Z., & Wang, D. (2023). Editorial: Model-informed drug development and precision dosing in clinical pharmacology practice. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1224980
Vancouver
Hu K, Fu M, Huang X, He S, Jiao Z, Wang D. Editorial: Model-informed drug development and precision dosing in clinical pharmacology practice. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1224980
BibTeX
@article{Hu2023,
author = {Hu, Ke and Fu, Meng and Huang, Xueting and He, Sumei and Jiao, Zheng and Wang, Dongdong},
title = {Editorial: Model-informed drug development and precision dosing in clinical pharmacology practice},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1224980}
}
EUVIMED